The persistence of p190 BCR-ABL transcripts is associated with lower probability of molecular response to imatinib in early and late chronic phase CML patients.

被引：0
|
作者：
Garuti, A
Ibatici, A
Cirmena, G
Miglino, M
Varaldo, R
Nicoletta, C
Grasso, R
Pozzi, S
Podesta, M
Gobbi, M
Sessarego, M
Patrone, F
Frassoni, F
机构：
[1] Osped San Martino Genova, Dept HematoOncol, Ctr Cellule Staminali & Terapia Cellulare, Genoa, Italy
[2] Osped San Martino Genova, Dipartimento Med Interna, Genoa, Italy
[3] Osped San Martino Genova, Clin Ematol, Genoa, Italy
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
10.1182/blood.V106.11.3282.3282
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3282
引用
收藏
页码：917A / 918A
页数：2
相关论文
共 50 条
  • [21] Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α
    Merx, K
    Müller, MC
    Kreil, S
    Lahaye, T
    Paschka, P
    Schoch, C
    Weisser, A
    Kuhn, C
    Berger, U
    Gschaidmeier, H
    Hehlmann, R
    Hochhaus, A
    LEUKEMIA, 2002, 16 (09) : 1579 - 1583
  • [22] Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α
    K Merx
    MC Müller
    S Kreil
    T Lahaye
    P Paschka
    C Schoch
    A Weisser
    C Kuhn
    U Berger
    H Gschaidmeier
    R Hehlmann
    A Hochhaus
    Leukemia, 2002, 16 : 1579 - 1583
  • [23] KINETICS OF BCR-ABL TRANSCRIPTS IN PATIENTS WITH CHRONIC PHASE CIVIL (CML-CP) TREATED WITH IMATINIB MESYLATE (IM): A PREDICTOR OF RESPONSE AND PROGRESSION FREE SURVIVAL (PFS)
    Mahmoud, H. K.
    El Nahas, Y. H.
    Samra, M. A.
    Fattah, R. M. Abdel
    El Emary, M. A.
    El Metnawy, W. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 573 - 574
  • [24] Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
    Hanfstein, B.
    Shlyakhto, V.
    Lauseker, M.
    Hehlmann, R.
    Saussele, S.
    Dietz, C.
    Erben, P.
    Fabarius, A.
    Proetel, U.
    Schnittger, S.
    Krause, S. W.
    Schubert, J.
    Einsele, H.
    Hanel, M.
    Dengler, J.
    Falge, C.
    Kanz, L.
    Neubauer, A.
    Kneba, M.
    Stegelmann, F.
    Pfreundschuh, M.
    Waller, C. F.
    Spiekermann, K.
    Baerlocher, G. M.
    Pfirrmann, M.
    Hasford, J.
    Hofmann, W-K
    Hochhaus, A.
    Mueller, M. C.
    LEUKEMIA, 2014, 28 (10) : 1988 - 1992
  • [25] Consistent amounts of acute leukemia-associated p190(BCR/ABL) transcripts are expressed by chronic myelogenous leukemia patients at diagnosis.
    Saglio, G
    Pane, F
    Gottardi, E
    Frigeri, F
    Buonaiuto, MR
    Guerrasio, A
    DeMicheli, D
    Parziale, A
    Fornaci, MN
    Martinelli, G
    Salvatore, F
    BLOOD, 1995, 86 (10) : 1738 - 1738
  • [26] Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
    B Hanfstein
    V Shlyakhto
    M Lauseker
    R Hehlmann
    S Saussele
    C Dietz
    P Erben
    A Fabarius
    U Proetel
    S Schnittger
    S W Krause
    J Schubert
    H Einsele
    M Hänel
    J Dengler
    C Falge
    L Kanz
    A Neubauer
    M Kneba
    F Stegelmann
    M Pfreundschuh
    C F Waller
    K Spiekermann
    G M Baerlocher
    M Pfirrmann
    J Hasford
    W-K Hofmann
    A Hochhaus
    M C Müller
    Leukemia, 2014, 28 : 1988 - 1992
  • [27] Distribution of common BCR-ABL fusion transcripts and their impact on treatment response in Imatinib treated CML patients: A study from India
    Sazawal, Sudha
    Chhikara, Sunita
    Singh, Kanwaljeet
    Chaubey, Rekha
    Mahapatra, Manoranjan
    Seth, Tulika
    Saxena, Renu
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2019, 62 (02) : 256 - 260
  • [28] CO-EXPRESSION OF P190 AND P 210 BCR-ABL FUSION TRANSCRIPTS AND RESPONSE TO TKI THERAPY IN CHRONIC MYELOID LEUKEMIA: THE RET (RETE EMATOLOGICA TOSCANA) EXPERIENCE
    Biagiotti, C.
    Scappini, B.
    Pancani, F.
    Gozzini, A.
    Caciagli, B.
    Occhini, U.
    Birtolo, S.
    Innocenti, F.
    Ponziani, V.
    Santini, V.
    Bosi, A.
    HAEMATOLOGICA, 2013, 98 : 559 - 560
  • [29] Chronic Myeloid Leukemia (CML) Patients With Atypical e1a2 P190 BCR-ABL Translocation Show a Poor Response To Therapy With Tyrosine Kinase Inhibitors (TKI)
    Montoriol-Sabate, Carme
    Martinez-Laperche, Carolina
    Jimenez-Gamiz, P.
    Collado, Rosa
    Minguela-Puras, Alfredo
    Pinan-Frances, M. A.
    Bellosillo, B.
    Martinez-Lopez, Joaquin
    Gonzalez, Marcos
    Larrayoz, Maria Jose
    Calasanz, MaJose
    Gomez-Casares, Maria Teresa
    Gonzalez-Brito, G.
    Soler, Gloria
    Roman, Jose
    Jimenez-Velasco, A.
    Buno, Ismael
    BLOOD, 2013, 122 (21)
  • [30] Impact of the Type of BCR-ABL Fusion Transcripts on Response and Survival in Patients with Chronic Phase CML Treated with Four Frontline TKI Modalities
    Jain, Preetesh
    Kantarjian, Hagop M.
    Luthra, Raja
    Gonzalez, Graciela Nogueras
    Jabbour, Elias
    Sasaki, Koji
    Romo, Carlos Guillermo
    Patel, Keyur P.
    Kadia, Tapan
    Borthakur, Gautam
    Estrov, Zeev
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge E.
    BLOOD, 2015, 126 (23)
12345